JP2023509421A5 - - Google Patents

Info

Publication number
JP2023509421A5
JP2023509421A5 JP2022540327A JP2022540327A JP2023509421A5 JP 2023509421 A5 JP2023509421 A5 JP 2023509421A5 JP 2022540327 A JP2022540327 A JP 2022540327A JP 2022540327 A JP2022540327 A JP 2022540327A JP 2023509421 A5 JP2023509421 A5 JP 2023509421A5
Authority
JP
Japan
Application number
JP2022540327A
Other languages
Japanese (ja)
Other versions
JP2023509421A (ja
JPWO2021138419A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/067463 external-priority patent/WO2021138419A1/en
Publication of JP2023509421A publication Critical patent/JP2023509421A/ja
Publication of JP2023509421A5 publication Critical patent/JP2023509421A5/ja
Publication of JPWO2021138419A5 publication Critical patent/JPWO2021138419A5/ja
Revoked legal-status Critical Current

Links

JP2022540327A 2019-12-31 2020-12-30 Sting活性に関連する状態を治療するための化合物および組成物 Revoked JP2023509421A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962955853P 2019-12-31 2019-12-31
US62/955,853 2019-12-31
US202063090547P 2020-10-12 2020-10-12
US63/090,547 2020-12-10
PCT/US2020/067463 WO2021138419A1 (en) 2019-12-31 2020-12-30 Compounds and compositions for treating conditions associated with sting activity

Publications (3)

Publication Number Publication Date
JP2023509421A JP2023509421A (ja) 2023-03-08
JP2023509421A5 true JP2023509421A5 (https=) 2025-06-25
JPWO2021138419A5 JPWO2021138419A5 (https=) 2025-06-25

Family

ID=74550729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022540327A Revoked JP2023509421A (ja) 2019-12-31 2020-12-30 Sting活性に関連する状態を治療するための化合物および組成物

Country Status (8)

Country Link
US (1) US20230115274A1 (https=)
EP (1) EP4085061A1 (https=)
JP (1) JP2023509421A (https=)
CN (1) CN115279770A (https=)
PY (1) PY2089151A (https=)
TW (1) TW202136255A (https=)
UY (1) UY39005A (https=)
WO (1) WO2021138419A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823036B (zh) 2018-07-03 2024-11-08 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
EP4267129A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
EP4267128A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
WO2022140397A1 (en) 2020-12-22 2022-06-30 Ifm Due, Inc. Methods of treating cancer
US20240060982A1 (en) 2020-12-22 2024-02-22 Ifm Due, Inc. Methods of treating cancer
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ifm Due有限公司 用於治療與sting活性相關的病狀之化合物及組合物
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
WO2024032597A1 (zh) * 2022-08-11 2024-02-15 杭州中美华东制药有限公司 具有sting抑制作用的酰胺类化合物及其药物组合物和用途
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
AU2023368953A1 (en) * 2022-10-28 2025-03-27 Boehringer Ingelheim International Gmbh Heterocyclic compounds as sting antagonists
CN117756698A (zh) * 2022-12-16 2024-03-26 中国药科大学 脲类化合物及其作为sting抑制剂的医药用途
CN116023321B (zh) * 2022-12-30 2024-11-29 中国药科大学 Sting抑制剂前药及其医药用途
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2006083005A1 (ja) * 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
WO2012062462A1 (en) * 2010-11-10 2012-05-18 Grünenthal GmbH Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands
WO2012075380A1 (en) 2010-12-03 2012-06-07 The Trustees Of The University Of Pennsylvania Tip60 inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
CN109394752A (zh) 2013-10-21 2019-03-01 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
EP3556362A1 (en) * 2018-04-16 2019-10-23 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
CN112823036B (zh) * 2018-07-03 2024-11-08 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物

Similar Documents

Publication Publication Date Title
CN305967414S (https=)
CN306005121S (https=)
CN305535872S (https=)
CN305538849S (https=)
CN305536813S (https=)
CN305536253S (https=)
CN305536140S (https=)
CN305535494S (https=)
CN305535481S (https=)
CN305534880S (https=)
CN305534566S (https=)
CN305533501S (https=)
CN305532357S (https=)
CN305682062S (https=)
CN305531904S (https=)
CN305531890S (https=)
CN305531363S (https=)
CN305528954S (https=)
CN305527739S (https=)
CN305527732S (https=)
CN305527617S (https=)
CN305526830S (https=)
CN306168576S (https=)
CN306150763S (https=)
CN306150751S (https=)